Alerta

SELF-ASSEMBLED MUCOADHESIVE BIOPOLYMER PARTICLE RELEASE SYSTEM AND PREPARATION METHOD THEREOF

Resumen de: US20260108615A1

0000 The present invention relates to a mucoadhesive polymeric prodrug comprising a partially succinated polyvinyl alcohol (PVA-SA) with adjusted amount of hydroxyl and carboxyl pendant groups, which form an ester and/or amide linkage with amino and/or carboxyl and/or hydroxyl groups of biologically active compounds such as proteins, peptides, synthetic chemical, or natural products compounds (e.g. doxorubicin as an antitumor agent and antifibrotic drug). Preferably, said biologically active compounds are cysteamine (CYS) as the aminothiol compound and one compound selected from the group consisting of doxorubicin (DOX), ketoprofen (KETO), or 4-hydroxybenzyl alcohol (HBA). Moreover, the simultaneous presence of both hydroxyl and carboxyl groups in the partially succinated polyvinyl alcohol (PVA-SA) chain of the prodrug enables the self-assembled formation of 50-260 nm particles from the linear macromolecules and thus the drug release can be prolonged or adjusted. The present invention also relates to improving the mucoadhesive properties of the polymeric prodrug by the regulation of the amount of conjugated aminothiol compound. Further, the present invention relates to the method for producing said mucoadhesive polymeric prodrug, and nanoparticles of the said mucoadhesive polymeric prodrug.

MATRIX BOUND VESICLES (MBVS) CONTAINING IL-33 AND THEIR USE

Resumen de: AU2026202508A1

Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo. In additional embodiments, methods are disclosed for increasing myoblast differentiation. pr p r

SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS

Resumen de: US20260109976A1

0000 Provided herein are heterologous engineered mRNA molecules; and methods of making and using said synthetic engineered mRNAs to increase expression profiles.

PAMAM-BASED NANOPARTICLE PROTEIN DEGRADATION SYSTEM AND METHOD OF PREPARATION AND USE THEREOF

Resumen de: US20260108474A1

A PAMAM-based protein degradation system and a method of preparation and use thereof are provided. The protein degradation system comprises: a silica nanoparticle core; and a poly(amidoamine) dendrimer (PAMAM) layer coated on a surface of the silica nanoparticle, wherein the PAMAM layer is linked via amide bonds to three small-molecule ligands: MDM2 protein ligand Idasanutlin, GLUT1 protein ligand Lavendustin B and E3 ubiquitin ligase ligand Thalidomide-NH—CH2—COOH. The nanoparticle protein degradation system cooperatively degrades MDM2 protein and GLUT1 protein. This cooperative degradation strategy not only effectively suppresses proliferation and energy metabolism of tumor cells, but also significantly enhances the stability of p53 protein. By restoring the normal function of p53 protein, tumor cell growth is further inhibited, providing a new strategy for cancer therapy.

BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: US20260108473A1

0000 The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

BIO-PARTICLE ENCAPSULATED HYDROGEL USING AQUEOUS-TWO PHASE SYSTEM AND METHOD FOR PRODUCING SAME

Resumen de: AU2024362372A1

When a biological material sensitive to an external reaction is incorporated during hydrogel production, physical stimulation or chemical stimulation applied in conventional hydrogel production methods requires a sophisticated process and can affect the activity and structure of particles in the hydrogel. On the other hand, a hydrogel using an aqueous-two phase system and a method for producing same provided by the present invention can simultaneously achieve hydrogel formation and the encapsulation of desired nanoparticles in the hydrogel. The present invention has succeeded in simply concentrating desired nanoparticles in a hydrogel with a high yield. In addition, the present invention relates to a hydrogel using an aqueous-two phase system and a method for producing same, wherein concentration and hydrogel formation are simultaneously performed, and thus the time for producing the hydrogel is reduced and the cost is significantly reduced.

DAPTOMYCIN NANO-FORMULATION, METHOD FOR PREPARING SAME, AND USE THEREOF

Resumen de: WO2026081389A1

The present invention relates to the field of pharmaceutical technology, and in particular, to a daptomycin nano-FORMULATION, a method for preparing same, and use thereof. The method comprises: A, encapsulating daptomycin with a copolymer poly(lactic-co-glycolic acid) to give a nanoparticle (NP); and B, sonicating a cell membrane vesicle overexpressing RANK and the nanoparticle (NP) in a water bath for 3 min, and then sequentially extruding the mixture through polycarbonate membranes of 800 nm, 400 nm, and 200 nm to give the daptomycin nano-formulation. The weight ratio of the membrane protein to PLGA is 0.25. By the method of the present invention, a daptomycin nano-formulation targeting rheumatoid arthritis is successfully prepared. The daptomycin nano-formulation prepared by the present invention has good stability. The daptomycin nano-formulation of the present invention has good therapeutic effects against RA.

L-ERGOTHIONEINE-GOLD NANOPARTICLES AND PREPARATION METHOD AND APPLICATION THEREOF

Resumen de: US20260108633A1

0000 An application for the EGT-AuNPs in preparing contrast agents and/or antioxidants is provided, where the EGT-AuNPs include gold nanoparticles (AuNPs), the AuNPs are connected to L-ergothioneine (EGT) by gold-sulfur bonds, and the antioxidants include medicines for preventing and/or treating acute kidney injury (AKI). EGT-AuNPs with antioxidant activity are designed and synthesized through the combination of the higher imaging contrast of gold and the antioxidant natural product EGT, and they are ultra-small AuNPs, which achieve the combination of CT imaging and antioxidant effects, and are suitable for renal imaging, particularly for the early diagnosis and treatment of AKI, realizing the integration of diagnosis and treatment, circumventing the toxicity of contrast agents present in the conventional nanomaterials, lowering the serum creatinine and urea nitrogen levels, and reducing the degree of renal tubular damage.

ANTIBODY MRNA FOR TREATING SARS-CORONAVIRUS-2 DELTA INFECTION AND COMPOSITION INCLUDING SAME

Resumen de: US20260108597A1

0000 The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition including same, the composition exhibiting excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.

NANOEMULSION WITHOUT PROPYLENE GLYCOL

Resumen de: US20260108462A1

0000 The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.

POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441

Resumen de: US20260108503A1

Micelle compositions comprising a hedgehog pathway inhibitor and their use in treating skin diseases, conditions, or disorders, such as skin cancers, including basal cell carcinoma, are disclosed.

Cannabinoid based nanoplatform composition and methods for treating breast cancer by inhibiting VEGF

Resumen de: US20260108536A1

Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.

Cannabinoid Based Nanoplatform Composition and Methods for treating knee osteoarthritis

Resumen de: US20260108539A1

This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.

CONFORMATIONALLY TUNABLE LIPID COMPOSITIONS AND THERAPEUTIC USES THEREOF

Resumen de: WO2026084761A2

Disclosed are lipid nanoparticle formulations comprising a lipidoid as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses a pharmaceutical composition comprising a lipidoid composition of the invention.

PROCESS FOR INSERTING TARGETING LIGAND INTO A LIPID NANOPARTICLE ENCAPSULATING NUCLEIC ACID AND COMPOSITIONS PRODUCED THEREFROM

Resumen de: US20260108475A1

Methods for inserting a targeting moiety (such as an antigen-binding protein moiety, a fragment antigen-binding moiety, or the like) into a lipid nanoparticle and compositions resulting from such methods are provided. The methods generally utilize a reaction that forms targeted nanoparticles by combining a targeting moiety and a lipid nanoparticle. A quenching operation is then provided by cooling the reaction to a temperature that stops the insertion of the targeting moiety. The reaction substantially preserves the integrity of a nucleic acid cargo (such as an mRNA encoding a VHH binding molecule).

LIPID NANOPARTICLES AND METHODS OF USE

Resumen de: WO2026085256A1

The present disclosure relates to lipids and compositions thereof. In various aspects of the disclosure, the compositions are lipid nanoparticle compositions that are used as adjuvants used with vaccines, such as RNA vaccines, and/or to prevent or treat diseases or disorders in a subject in need thereof.

COMPOSITION FOR THE TREATMENT OR PREVENTION OF UNWANTED IMMUNE RESPONSES

Resumen de: WO2026082856A1

The invention relates to a composition for use in the treatment or prevention of one or more unwanted immune responses in a subject, wherein the one or more unwanted immune responses are caused by the use of one or more immunogenic drugs and wherein the composition comprises negatively charged non-polymeric nanoparticles, wherein the negatively charged non-polymeric nanoparticles are selected from the group consisting of at least one of silicon particles, solid lipid particles comprising at least one immune modulating drug and liposomes comprising at least one immune modulating drug.

NON-PEGYLATED LIPID NANOPARTICLES

Resumen de: US20260108622A1

Provided herein are non-PEGylated lipid nanoparticles comprising an outer polyanionic layer, compositions thereof, and methods of using said particles or compositions for therapeutic applications.

NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION

Resumen de: US20260108463A1

The present invention relates to a composition comprising an oil in water nanoemulsion and a highly lipophilic macrolide lactone as active agent, such as tacrolimus, dissolved in the nanoemulsion. In this formulation, tacrolimus can be fully dissolved, rather than suspended, and shows an improved stability in terms of active substance content, pH, particle size and particle size homogeneity.

A POLYMER BASED DELIVERY SYSTEM FOR ADMINISTRATION OF ANTI-CANCER AGENTS

Resumen de: WO2026084669A1

The present invention is directed to polymer-drug conjugates and/or compositions and/or nanoparticles comprising anti-cancer agents. The present invention is also directed to polymer- drug conjugates and/or compositions comprising docetaxel and the administration of docetaxel derivatives for the treatment of a number of diseases. The present invention is also directed to polymer-drug conjugates and/or compositions comprising gemcitabine or combretastatin A4 for the treatment of a number of diseases.

METHOD FOR PREPARING BIOTIC SUPERPARAMAGNETIC NANOPARTICLES DERIVED FROM COLCHICUM RITCHII

Resumen de: US20260108577A1

A method of preparing biotic super-paramagnetic nanoparticles can include combining a Colchicum ritchii plant extract with a ferric chloride solution to provide a mixture and adding sodium hydroxide solution to the mixture to provide the super-paramagnetic nanoparticles.

CANNABINOID BASED NANOPLATFORM COMPOSITION AND METHODS FOR TREATING MENOPAUSE SYMPTOMS

Resumen de: US20260108538A1

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

Integrative Treatment for Shingles Based on Cannabinoid Compounds

Resumen de: US20260108537A1

This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.

RAPIDLY METABOLIZABLE IONIZABLE LIPID COMPOUND

Resumen de: WO2026082030A1

Provided in the present invention is an ionizable lipid compound. Specifically, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof. Further provided in the present invention are a nanoparticle pharmaceutical composition containing the compound, and the use of the compound and composition thereof in the delivery of nucleic acids.

NANOPARTICLE COMPOSITIONS

Nº publicación: WO2026083169A2 23/04/2026

Solicitante:

TRAKIA UNIV [BG]

Resumen de: WO2026083169A2

The present invention relates to natural nanocarriers or nanoparticles with biocompatible, biodegradable, hypoallergenic, environmentally and physiologically acceptable properties. More in particular, it can be stated that the present invention relates to natural biopolymer nanocarriers, nanoparticles or nano-spheres with biocompatible, biodegradable, environmentally and physiologically acceptable properties as vehicles for physiological and environmentally safe delivery of active ingredients. The present invention also relates to nanoparticle compositions, methods of making the nanoparticles and nanoparticles compositions, as well as uses thereof.